Form 4: Cidara Therapeutics Director Chrysa Mineo Granted 11,100 Stock Options

Cidara Therapeutics, Inc. Director Chrysa Mineo was granted 11,100 stock options with an exercise price of $21.31, vesting over approximately one year.

Summary

• Chrysa Mineo, a Director of Cidara Therapeutics, Inc. (CDTX), was granted 11,100 stock options.
• The options have an exercise price of $21.31 per share.
• The transaction date for this grant was June 18, 2025.
• The options are set to expire on June 17, 2035.
• Vesting for these options will occur on the earlier of June 18, 2026, or the day prior to the Issuer's 2026 annual meeting of stockholders.
• Following this transaction, Ms. Mineo directly beneficially owns 11,100 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Neutral to slightly positive, as it represents a standard compensation event that aligns director interests with shareholders, without indicating any immediate operational or financial changes.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term company performance.
• It represents a standard form of compensation for board members, indicating ongoing commitment.

Negatives

• Potential for future dilution if the options are exercised, although this is a common aspect of equity compensation.

Risks

• No specific risks are detailed in this Form 4 filing, as it primarily reports a transaction.

Future Outlook

The stock options are subject to a vesting schedule, indicating that the shares will become exercisable on the earlier of June 18, 2026, or the day prior to the Issuer's 2026 annual meeting of stockholders, aligning future incentives.

Management Comments

• No direct quotes from management are provided in this Form 4 filing. The filing was signed by Shane Ward, Attorney-in-Fact.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industries, used to attract and retain talent and align leadership interests with long-term company performance.

Comparison to Industry Standards

• The specific value and terms of this option grant would typically be evaluated against compensation practices for directors at peer companies within the biotechnology sector, considering company size, stage of development, and market capitalization.
• Without specific peer company compensation data, a direct comparison of the grant size (11,100 options) or exercise price ($21.31) to industry benchmarks is not possible from this document alone.

Related Party Transactions

• The grant of stock options to Chrysa Mineo, a Director, constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also improved alignment of director incentives with shareholder value creation.

Next Steps

• The stock options will vest on the earlier of June 18, 2026, or the day prior to the Issuer's 2026 annual meeting of stockholders.
• Upon vesting, the director will have the right to exercise the options to acquire common stock.

Key Dates

Keywords

Cidara Therapeutics, CDTX, Stock Options, Director Compensation, Insider Transaction, Form 4, Equity Grant, Chrysa Mineo